Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals said the U.S. FDA approved its romidepsin injection solution (27.5 mg/5.5 mL) in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy status, granting 180 days of market exclusivity, and references a former Teva formulation. IQVIA data cited by Amneal put U.S. sales of romidepsin lyophilized powder at about $78 million for 12 months ended April 2026.
FDA approval of a more convenient romidepsin formulation should support incremental demand and strengthen Amneal’s oncology injectables position via CGT exclusivity.
Amneal received FDA approval for ready-to-use romidepsin injection solution, expanding its differentiated injectables portfolio and enabling CGT exclusivity.
Near-term upside bias as investors price in incremental sales/exclusivity; magnitude likely moderate absent full commercial uptake data.
Background
Romidepsin injection solution is a histone deacetylase inhibitor for cutaneous T-cell lymphoma after prior systemic therapy; the approved product references the former Teva formulation that was withdrawn.
Why it matters
The ready-to-use presentation removes reconstitution steps, which can reduce operational burden and improve consistency for hospitals/pharmacies, potentially supporting faster adoption versus lyophilized options.
Market relevance
A concrete regulatory approval with CGT exclusivity is a tradable catalyst for AMRX, with potential incremental sales supported by a referenced prior-product sales figure.
Market effects
Reinforces demand for differentiated, ready-to-use oncology injectables and highlights CGT pathway value for complex generics.
Limited; primary impact is company-specific in the US oncology drug market.
Moderate; FDA approval can influence broader competitive dynamics for romidepsin formulations internationally.
Alternative perspectives
CGT exclusivity (180 days) may not translate into large revenue impact if hospital procurement shifts slowly or if competition re-enters quickly post-exclusivity.
Actual uptake will depend on formulary inclusion, contracting/pricing versus the withdrawn Teva product, and supply reliability versus existing alternatives.
Key entities
- companyAmneal Pharmaceuticals, Inc.
FDA-approved ready-to-use romidepsin injection solution under CGT with 180 days of market exclusivity.
- regulatorU.S. Food and Drug Administration (FDA)
Approved the romidepsin injection solution and enabled CGT designation.
- productRomidepsin injection solution
Ready-to-use 27.5 mg/5.5 mL single-dose vials for cutaneous T-cell lymphoma.
